Jun 8, 2026 · 11 min · 10 segments
In this episode of Bench to Boardroom, we examine why maximizing value across a life sciences portfolio increasingly requires an asset-specific, geography-agnostic approach rather than relying on the…
The new economics of launch, why, where you launch, may matter more than what you launch.
Today's discussion begins with a statement that may sound obvious.
but whose implications are profound.
Every investment decision in innovative therapeutics should ultimately be judged by one metric, net present value.
Not headlines, not scientific elegance, not conference presentations, not even regulatory approval, value creation.
And yet, despite billions invested annually in drug development, many organizations still make commercialization decisions based on historical precedent rather than maximizing portfolio and PV.
Ironically, some of the largest opportunities to create value no longer reside inside the laboratory.
They reside in strategy.
Specifically, where should we launch first? Because the traditional answer, United States first, Europe second, rest of the world later, is increasingly becoming an assumption rather than a conclusion.
And assumptions are expensive.
Today we'll discuss why value creation across a portfolio increasingly requires asset-specific thinking and geography-agnostic decision-making.
The new economics of launch, why, where you launch, may matter more than what you launch.
Today's discussion begins with a statement that may sound obvious.
but whose implications are profound.
Every investment decision in innovative therapeutics should ultimately be judged by one metric, net present value.
Not headlines, not scientific elegance, not conference presentations, not even regulatory approval, value creation.
And yet, despite billions invested annually in drug development, many organizations still make commercialization decisions based on historical precedent rather than maximizing portfolio and PV.
Ironically, some of the largest opportunities to create value no longer reside inside the laboratory.
They reside in strategy.
Specifically, where should we launch first? Because the traditional answer, United States first, Europe second, rest of the world later, is increasingly becoming an assumption rather than a conclusion.
And assumptions are expensive.
Today we'll discuss why value creation across a portfolio increasingly requires asset-specific thinking and geography-agnostic decision-making.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
